By Peptide Insider Research Team · 11 min read · Last updated September 3, 2026
SLU-PP-332 is a synthetic small-molecule agonist of the estrogen-related receptors (ERRα, ERRβ and ERRγ) that has attracted attention in metabolic research as a candidate "exercise-mimetic" chemical probe. Unlike the growth-hormone secretagogues and repair peptides frequently discussed in this niche, SLU-PP-332 is not a peptide at all — it is an acylhydrazone that engages a family of orphan nuclear receptors governing mitochondrial energy metabolism. This review summarizes the reported mechanism, preclinical evidence base, and research limitations. All content is provided strictly for research reference.
Research snapshot
| Attribute | Reported characterization |
|---|---|
| Compound class | Synthetic acylhydrazone (4-hydroxybenzohydrazide derivative) — not a peptide |
| Molecular target | Estrogen-related receptors ERRα, ERRβ, ERRγ (pan-agonist) |
| Reported potency | Preferential ERRα activity (EC50 ≈ 98 nM in reporter assays) [3] |
| Primary mechanism | Stabilizes active ERR conformation; promotes PGC-1α/β coactivator recruitment [1,3] |
| Developer | Burris laboratory, Saint Louis University [3] |
| Evidence maturity | Preclinical only — in-vitro assays and rodent models; no human trials [3,4] |
| Known limitation | Poor oral bioavailability; successor analog SLU-PP-915 under study [2,3] |
On this page
- Introduction
- Is SLU-PP-332 a peptide?
- Biological background: the ERR family
- Structure and mechanism of action
- Evidence by research domain
- Limitations and research considerations
- Where to source for research
- Frequently asked research questions
- Works Cited
Introduction
The search for pharmacological tools that reproduce aspects of aerobic exercise at the transcriptional level has centered on a small set of nuclear-receptor and coactivator pathways. Among the compounds studied in this context, SLU-PP-332 has become one of the most cited chemical probes because it directly activates the estrogen-related receptors (ERRs) — transcription factors that sit at the heart of mitochondrial and oxidative metabolism [1,3]. Investigators have used SLU-PP-332 to ask a mechanistic question: if the ERR–PGC-1 axis is engaged pharmacologically, do skeletal muscle and other high-demand tissues adopt gene-expression signatures resembling those induced by endurance training?
Reported rodent data suggest that they do, at least in part. However, the compound has been characterized only in animal and cell-based systems, and popular framing of SLU-PP-332 as "exercise in a pill" overstates what a single receptor agonist can accomplish [4]. This review keeps to the peer-reviewed record and treats the compound as what it is: a research-use-only investigational probe.
Is SLU-PP-332 a peptide?
No. SLU-PP-332 is frequently indexed alongside research peptides in supplier catalogs and discussion forums, but it is chemically a small-molecule acylhydrazone, not a chain of amino acids [3]. This distinction matters for research handling and interpretation: it acts as a direct ligand for intracellular nuclear receptors rather than engaging a cell-surface receptor as most signaling peptides do. Researchers comparing SLU-PP-332 with peptide agents such as MOTS-c or AOD-9604 should treat it as a mechanistically separate class — a transcription-factor modulator rather than a peptide hormone or fragment.
Biological background: the ERR family
Estrogen-related receptors were the first orphan nuclear receptors identified, and despite decades of study no endogenous hormone ligand has been confirmed for the subfamily [5]. Rather than being switched on by a circulating hormone, ERRs are constitutively active transcription factors whose output is set largely by the availability of the PGC-1 (PPARγ coactivator-1) family of coregulators, which act as functional protein "ligands" [5]. Where PGC-1α is abundant — in mitochondria-rich tissues such as heart, skeletal muscle and kidney — ERRs drive the expression of gene networks for mitochondrial biogenesis, oxidative phosphorylation and fatty-acid β-oxidation [5].
ERRα in particular regulates fatty-acid handling genes including medium-chain acyl-CoA dehydrogenase (MCAD) and carnitine palmitoyltransferase 1 (CPT1), and it has been reported to bind the PPARα promoter directly, positioning ERRα upstream of a broader cardiac and skeletal-muscle metabolic program [6]. Because this circuitry is the same one remodeled by endurance exercise, the ERRs became an obvious target for compounds intended to probe exercise-associated adaptation.
Structure and mechanism of action
SLU-PP-332 binds within the ligand-binding domain of the ERRs and stabilizes their active conformation, which favors recruitment of PGC-1α and PGC-1β and, in turn, activation of ERR target genes [1,3]. In reporter assays the compound behaves as a pan-agonist across ERRα, ERRβ and ERRγ, with preferential potency for ERRα (EC50 ≈ 98 nM) [3]. Downstream, reported signatures in treated cells and tissues include upregulation of PGC-1α itself, pyruvate dehydrogenase kinase 4 (PDK4) — which shifts fuel preference toward fatty acids — and components of the electron transport chain [1,3].
In skeletal muscle, investigators described an ERRα-dependent acute aerobic-exercise gene program after SLU-PP-332 administration, including markers of oxidative fiber specification [3]. The mechanistic claim is therefore specific: the compound does not add a novel pathway but amplifies an endogenous one that endurance training also engages.
Evidence by research domain
The reported preclinical literature spans several organ systems. All findings below derive from rodent models or cell culture and are summarized for research reference only.
| Research domain | Typical models | Reported findings | Evidence maturity |
|---|---|---|---|
| Skeletal muscle / endurance | C57BL/6J mice; myoblast cultures | ERRα-dependent oxidative gene program; increased treadmill running distance/time; oxidative fiber shift [3] | Preclinical, multiple reports |
| Metabolic syndrome | Diet-induced obese and ob/ob mice | Reduced fat mass, improved insulin sensitivity, increased fatty-acid oxidation without change in food intake [4] | Preclinical |
| Cardiac function | Transverse aortic constriction (pressure-overload) mice | Improved ejection fraction, reduced fibrosis, restored fatty-acid metabolism via ERRγ; SLU-PP-915 analog used for oral dosing [2] | Preclinical, single-model |
| Muscle maintenance / aging | Myoblast differentiation; atrophy models | Reported promotion of myoblast differentiation and mitigation of atrophy signatures [7] | Early/exploratory |
| Receptor pharmacology | In-vitro reporter and coactivator assays | Pan-ERR agonism, ERRα preference, PGC-1 recruitment [1,3] | Mechanistic, well-replicated |
Skeletal muscle and endurance
The foundational characterization reported that SLU-PP-332 induced an ERRα-dependent acute aerobic-exercise response in mouse skeletal muscle and enhanced exercise capacity, with treated animals covering greater treadmill distance than vehicle controls [3]. Subsequent work has explored whether the same axis supports myoblast differentiation and resistance to atrophy in sedentary or aging contexts [7].
Metabolic and cardiac research
In obese and leptin-deficient mice, a synthetic ERR agonist was reported to alleviate features of metabolic syndrome — lower fat mass and improved insulin sensitivity — while leaving food intake unchanged, implicating energy expenditure rather than appetite suppression [4]. In pressure-overload heart failure, ERR agonism was associated with improved cardiac function and reduced fibrosis, attributed largely to ERRγ-mediated restoration of fatty-acid metabolism in cardiomyocytes [2].
Limitations and research considerations
- Species and model dependence. Every efficacy observation to date comes from rodents or cultured cells; no human clinical trial data exist, and translation to human physiology is unestablished [3,4].
- Pharmacokinetics. SLU-PP-332 has poor oral bioavailability, a limitation that prompted development of successor analogs such as SLU-PP-915 for research requiring oral exposure [2,3].
- Overstated framing. The "exercise mimetic" label is a mechanistic shorthand; a single ERR agonist cannot reproduce the coordinated, multi-system, mechanically loaded response of physical exercise [4].
- No toxicology profile for human use. Formal safety and toxicology characterization in humans has not been reported; the compound is a laboratory tool only [3].
- Analytical identity. Because it is often mislabeled as a peptide, researchers should confirm identity and purity by mass spectrometry and HPLC on any received material.
Where to source for research
SLU-PP-332 is offered by several suppliers that serve the research community, and comparing certificates of analysis across vendors is standard practice before any laboratory work. Among suppliers that publish analytical documentation, Short Chain Aminos lists research compounds with batch-level reference data. BioPep, Catalyst Research, and Apex Research Services similarly provide catalog entries and purity documentation used by laboratories evaluating small-molecule and peptide research materials. For guidance on assessing vendors, see our laboratory buyer's guide. Availability is noted here for research reference only and is not an endorsement or a recommendation for any use.
Frequently asked research questions
What is SLU-PP-332?
SLU-PP-332 is a synthetic small-molecule pan-agonist of the estrogen-related receptors ERRα, ERRβ and ERRγ. In preclinical rodent studies it activates a gene program associated with mitochondrial biogenesis and fatty-acid oxidation, which is why it is described as an exercise-mimetic research probe [1,3].
Is SLU-PP-332 a peptide?
No. Although it is often catalogued with research peptides, SLU-PP-332 is chemically an acylhydrazone small molecule, not an amino-acid chain. It acts on intracellular nuclear receptors rather than a cell-surface peptide receptor [3].
What does SLU-PP-332 do at the molecular level?
It binds the ligand-binding domain of the ERRs, stabilizes their active state, and promotes recruitment of PGC-1α/β coactivators. This upregulates targets such as PDK4 and electron-transport-chain genes in reported cell and rodent models [1,3].
Has SLU-PP-332 been tested in humans?
No published human clinical trials exist. All efficacy and safety observations derive from in-vitro assays and mouse studies, and the compound is not approved for human use [3,4].
How does SLU-PP-332 differ from research peptides like MOTS-c?
Both are studied in metabolic contexts, but MOTS-c is a mitochondrial-derived peptide while SLU-PP-332 is a small-molecule nuclear-receptor agonist. They engage different molecular machinery and are separate compound classes [3].
Why is SLU-PP-915 mentioned alongside SLU-PP-332?
SLU-PP-332 has poor oral bioavailability, so investigators developed SLU-PP-915 as a successor analog with improved pharmacokinetics for studies requiring oral administration in animal models [2,3].
Works Cited
- Billon C, Sitaula S, Banerjee S, et al. Synthetic ERRα/β/γ agonist induces an ERRα-dependent acute aerobic exercise response. ACS Chemical Biology. 2023;18(4):756–771. DOI: 10.1021/acschembio.2c00720. PMID: 36988910.
- Xu W, Billon C, Li H, et al. Novel pan-ERR agonists ameliorate heart failure through enhancing cardiac fatty acid metabolism and mitochondrial function. Circulation. 2024;149(3):227–243. DOI: 10.1161/CIRCULATIONAHA.123.066542.
- Billon C, et al. Characterization of the ERR pan-agonist SLU-PP-332 as a chemical probe. Journal of Pharmacology and Experimental Therapeutics. 2024. DOI: 10.1016/j.jpet.2024.100015.
- Billon C, Schoepke E, Avdagic A, et al. A synthetic ERR agonist alleviates metabolic syndrome. Journal of Pharmacology and Experimental Therapeutics. 2024;388(2):232–240.
- Giguère V. Transcriptional control of energy homeostasis by the estrogen-related receptors. Endocrine Reviews. 2008;29(6):677–696. PMID: 18664618.
- Huss JM, Torra IP, Staels B, Giguère V, Kelly DP. Estrogen-related receptor α directs peroxisome proliferator-activated receptor α signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle. Molecular and Cellular Biology. 2004;24(20):9079–9091. PMID: 15456881.
- Frontiers in Physiology. ERR agonism and myoblast differentiation in atrophy models. Frontiers in Physiology. 2025;16:1616693. DOI: 10.3389/fphys.2025.1616693.
Research Use Only. All content is provided strictly for research reference and is not for human or veterinary use. Nothing herein constitutes medical, dosing, or therapeutic guidance. SLU-PP-332 is an investigational research chemical with no approved human application.
Explore related compounds: MOTS-c · 5-Amino-1MQ · AOD-9604